[Biologic agents in COPD management]

M Gueçamburu; M Zysman

doi:10.1016/j.rmr.2023.11.003

[Biologic agents in COPD management]

Rev Mal Respir. 2024 Feb;41(2):127-138. doi: 10.1016/j.rmr.2023.11.003. Epub 2023 Dec 20.

[Article in French]

Authors

M Gueçamburu¹, M Zysman²

Affiliations

¹ Service des maladies respiratoires, CHU de Bordeaux, Centre François-Magendie, hôpital Haut-Lévêque, hôpital Haut Lévèque, avenue de Magellan, 33604 Pessac, France. Electronic address: marina.guecamburu@live.fr.
² Service des maladies respiratoires, CHU de Bordeaux, Centre François-Magendie, hôpital Haut-Lévêque, hôpital Haut Lévèque, avenue de Magellan, 33604 Pessac, France; U1045, CIC 1401, Univ-Bordeaux, Centre de Recherche cardio-thoracique de Bordeaux, 33604 Pessac, France.

PMID: 38129268
DOI: 10.1016/j.rmr.2023.11.003

Abstract

Chronic obstructive pulmonary disease (COPD) is a frequently occurring disease entailing high morbidity and mortality, and relevant therapeutic resources are limited. As is the case with asthma, the current trend consists in the phenotyping of COPD patients so as to develop personalized medicine tailored to a given individual's inflammatory profile. The aim of this review is to summarize the role of biologic agents in the management of COPD, taking into consideration not only COPD pathophysiology, but also the previously published studies and the relatively encouraging prospects for the future.

Keywords: BPCO; Biologics; Biomarker; Biomarqueur; Biothérapies; COPD; Médecine personnalisée; Personalized medicine; Phenotype; Phénotype.

Publication types

English Abstract
Review

MeSH terms

Asthma* / drug therapy
Biological Products* / therapeutic use
Humans
Precision Medicine
Pulmonary Disease, Chronic Obstructive* / drug therapy

Substances

Biological Products